Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CLK1 | P49759 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 5/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | RAB9A | P51151 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.45 |
| ▸ | GFER | P55789 | 1/20 | 0.45 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.45 |
| ▸ | RELA | Q04206 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4940739 | 0.90 | CYP1A2 (0.49) | CLK1CYP1A2CYP2C19MAPTALDH1A1 | |
| SCHEMBL1450749 | 0.78 | HDAC6 (0.55) | CLK1MAPTALDH1A1RAB9AKMT2A | |
| SCHEMBL28366866 | 0.77 | CYP1A2 (0.50) | CYP1A2CYP2C19MAPTALDH1A1RAB9A | |
| SCHEMBL3250178 | 0.76 | LOXL2 (0.67) | CLK1MAPTALDH1A1RAB9AKMT2A | |
| SCHEMBL20710415 | 0.74 | MAPT (0.65) | CYP1A2CYP2C19MAPTALDH1A1RAB9A | |
| SCHEMBL8304545 | 0.73 | KMT2A (0.54) | CYP1A2CYP2C19MAPTALDH1A1RAB9A | |
| SCHEMBL5226064 | 0.72 | TRPV1 (0.55) | CYP1A2CYP2C19 | |
| SCHEMBL5227899 | 0.71 | CYP1A2 (0.39) | CYP1A2CYP2C19MAPTALDH1A1RAB9A | |
| SCHEMBL20746310 | 0.71 | ALDH1A1 (0.51) | CLK1CYP1A2MAPTALDH1A1RAB9A | |
| SCHEMBL5232715 | 0.71 | CYP1A2 (0.39) | CYP1A2CYP2C19MAPTALDH1A1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080114041-A1 | Benzothiazolesulfonamides | ASTRAZENECA AB (SE) | 2008-05-15 | — | — | US | claimed |
| EP-1833808-A1 | NEW BENZOTHIAZOLESULFONAMIDES | AstraZeneca AB (SE) | 2007-09-19 | — | — | EP | claimed |
| US-20060223868-A1 | Heterocyclic amides exhibiting and inhibitory activity at the vanilloid receptor 1(vr1) | ASTRAZENECA AB (SE) | 2006-10-05 | — | — | US | claimed |
| WO-2006068593-A1 | NEW BENZOTHIAZOLESULFONAMIDES | ASTRAZENECA AB (SE) | 2006-06-29 | — | — | WO | claimed |
| EP-1622884-A1 | NEW HETEROCYCLIC AMIDES EXHIBITING AN INHIBITORY ACTIVITY AT THE VANILLOID RECEPTOR 1 (VR1). | AstraZeneca AB (SE) | 2006-02-08 | — | — | EP | claimed |
| WO-2004096784-A1 | NEW HETEROCYCLIC AMIDES EXHIBITING AN INHIBITORY ACTIVITY AT THE VANILLOID RECEPTOR 1 (VR1). | ASTRAZENECA AB (SE) | 2004-11-11 | — | — | WO | claimed |
| US-20080114041-A1 | Benzothiazolesulfonamides | ASTRAZENECA AB (SE) | 2008-05-15 | — | — | US | disclosed |
| EP-1833808-A1 | NEW BENZOTHIAZOLESULFONAMIDES | AstraZeneca AB (SE) | 2007-09-19 | — | — | EP | disclosed |
| EP-1799661-A1 | NEW HYDROXYMETHYLBENZOTHIAZOLES AMIDES | AstraZeneca AB (SE) | 2007-06-27 | — | — | EP | disclosed |
| US-20060223868-A1 | Heterocyclic amides exhibiting and inhibitory activity at the vanilloid receptor 1(vr1) | ASTRAZENECA AB (SE) | 2006-10-05 | — | — | US | disclosed |
| WO-2006068593-A1 | NEW BENZOTHIAZOLESULFONAMIDES | ASTRAZENECA AB (SE) | 2006-06-29 | — | — | WO | disclosed |
| WO-2006038871-A1 | NEW HYDROXYMETHYLBENZOTHIAZOLES AMIDES | ASTRAZENECA AB (SE) | 2006-04-13 | — | — | WO | disclosed |
| EP-1622884-A1 | NEW HETEROCYCLIC AMIDES EXHIBITING AN INHIBITORY ACTIVITY AT THE VANILLOID RECEPTOR 1 (VR1). | AstraZeneca AB (SE) | 2006-02-08 | — | — | EP | disclosed |
| WO-2004096784-A1 | NEW HETEROCYCLIC AMIDES EXHIBITING AN INHIBITORY ACTIVITY AT THE VANILLOID RECEPTOR 1 (VR1). | ASTRAZENECA AB (SE) | 2004-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060223868-A1 | Heterocyclic amides exhibiting and inhibitory activity at the vanilloid receptor 1(vr1) | AVPR1A, AVPR2, TRPV1 | CLK1 4223/4885CYP1A2 745/4885CYP2C19 594/4885 |
| US-20080114041-A1 | Benzothiazolesulfonamides | SULT1E1, TST, SULT1A1 | CLK1 4417/4885CYP1A2 467/4885CYP2C19 164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.